# Applicant

Focus Diagnostics, Inc. 10703 Progress Way Cypress, California 90630 USA

# Establishment Registration No.

2023365

# Contact Person

Constance Bridges   
Sid Mathur (Alternate Contact)   
tel 714.220.1900   
fax 714.995.6921   
cbridges@focusdx.com   
smathur@focusdx.com

# Summary Date

September 24, 2007

Proprietary Name Generic Name Classification Predicate Device

PlexusTM HerpeSelect® HSV 1 and 2 IgG (with software) Herpes Simplex Virus Types 1 and 2 Serological Assays Class II HerpeSelect 1 and 2 Immunoblot IgG

# Device Description

The Focus Diagnostics Plexus™M HerpeSelect $\textsuperscript { \textregistered }$ HSV 1 and $2 ~ \mathrm { I g G }$ (with software) is a multiplexed immunoassay for qualitaively etetig an fetiahuman IGantibodie to HSV- and HSV-.Test principl s enl t the predicate device.

# Intended Use

The Focus Diagnostics PlexusT HerpeSelect $\textsuperscript { \textregistered }$ HSV 1 and $2 ~ \mathrm { { I g G } }$ (with software) is intended for qualitatively detecting the presence or absence of human IgG antibodies to HSV-1 and HSV-2 in human sera. The test is inicatd or pregant woen nd sexually ctiv aduls, as anidor prestively dagosg HSV- and HSV-2 likelihood of HSV-1 and HSV-2 infection. The test is not intended for donor screening or for self-testing. The peoancehis assyhas ot bee establishe rus  pediaipoulatin, rnenatalsce testing o mmunoompromised patients, for use by a point f care facility oror use with automated equiment.

# Test Principle

The Focus Diagnostics HerpeSelect ${ \mathfrak { P } } _ { 1 }$ and 2 Plexus IgG uses an Antigen Bead suspension that contains two distinct HSVntn betyeha  if av ndo- b nd G- eTheF Diagnostics HerpeSelect ${ \mathfrak { P } } _ { 1 }$ and 2 Multiplex IgG is a three step procedure.

1. Pnt ilu n hediu cba wint Beas Hnd e, then the antibodies bind to the corresponding antigen beads. 2. Phycoerythrin—conjugated goat anti-human IgG, (Conjugate) is added, and the Conjugate binds to the bound HSV antibody (if present), and forms a Conjugate-HSV antibody-antigen bead sandwich. 3. Fluorescence from each distinct HV antigen bead type ismeasure and compared against a Cut-off Calia.

# Performance Characteristics

# Studies to Validate Plexus™ HerpeSelect® HSV 1 and $2 \mathrm { { I g } G }$ (with software)

Testng was one  exteal s nd  teal   nm that ass esultta usiu Software are identical to results calculated manually using the instrument (Luminex) raw data.

<table><tr><td rowspan=1 colspan=3>Agreement between Index Calculated with Plexus Software and Index Calculated Manually (n = 600)</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>% Agreement; 95% Confidence Interval</td></tr><tr><td rowspan=1 colspan=1>HSV-1 Pos</td><td rowspan=1 colspan=1>161/161</td><td rowspan=1 colspan=1>100%; 95% CI: 0.977 - 1.00</td></tr><tr><td rowspan=1 colspan=1>HSV-1 Eqv</td><td rowspan=1 colspan=1>4/4</td><td rowspan=1 colspan=1>100%; 95% CI: 0.398 - 1.00</td></tr><tr><td rowspan=1 colspan=1>HSV-1 Neg</td><td rowspan=1 colspan=1>134/134</td><td rowspan=1 colspan=1>100%; 95% CI: 0.973 - 1.00</td></tr><tr><td rowspan=1 colspan=1>HSV-1 Invalid</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>HSV-2 Pos</td><td rowspan=1 colspan=1>139/139</td><td rowspan=1 colspan=1>100%; 95% CI: 0.974 - 1.00</td></tr><tr><td rowspan=1 colspan=1>HSV-2 Eqv</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>100% ; 95% CI: 0.590 - 1.00</td></tr><tr><td rowspan=1 colspan=1>HSV-2 Neg</td><td rowspan=1 colspan=1>153/153</td><td rowspan=1 colspan=1>100%; 95% CI: 0.976 - 1.00</td></tr><tr><td rowspan=1 colspan=1>HSV-1 Invalid</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1></td></tr></table>

$100 \%$ of HSV-1 indexes and $100 \%$ of HSV-2 indexes calculated using the Plexus software matched the indexes calculated manually.

Summary of Previous Sudies fr Plexus HerpeSelect®   an $\mathbf { 2 \ U g G }$ (manual calculation)   

<table><tr><td rowspan=1 colspan=1>Study</td><td rowspan=1 colspan=1>PlexusHerpeSelect 1Results</td><td rowspan=1 colspan=1>PlexusHerpeSelect 2Results</td></tr><tr><td rowspan=1 colspan=1>Pregnant Women (Indicated population)                   SpecificitySensitivity</td><td rowspan=1 colspan=1>96.5%92.2%</td><td rowspan=1 colspan=1>94.3%95.5%</td></tr><tr><td rowspan=1 colspan=1>Sexually Active Adults (Indicated population)             SpecificitySensitivity</td><td rowspan=1 colspan=1>91.0%96.5%</td><td rowspan=1 colspan=1>96.3%97.4%</td></tr><tr><td rowspan=1 colspan=1>CDC HSV/CMV Panel                              Agreement with positivesAgreement with negatives</td><td rowspan=1 colspan=1>100%100%</td><td rowspan=1 colspan=1>100%100%</td></tr><tr><td rowspan=1 colspan=1>Low Prevalence Population                        Agreement with negatives</td><td rowspan=1 colspan=1>97.9%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Cross-reactivity with CMV, EBV and VZV.            Cross-reactivity</td><td rowspan=1 colspan=1>0-5%</td><td rowspan=1 colspan=1>0-3%</td></tr><tr><td rowspan=1 colspan=1>Reproducibility                                           %CV of positives</td><td rowspan=1 colspan=1>≤10%</td><td rowspan=1 colspan=1>≤10%</td></tr></table>

# K071511

# Sensitivity and Specificity with Pregnant Women $( \mathbf { n } = 3 0 0 )$

Focus $( \mathfrak { n } = 1 5 0 )$ and an external investigator $( \mathfrak { n } = 1 5 0 ) ,$ assessed the device's reactivity with sera from pregnant he   lyiheinaTheextelnv aUniversiy aboaoy ocatedinNorther Calioria, and the sera were colleted in he Pacic orthwester United States. The gold-standard reference method was the Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG or clculation  ensitivityan specificiy. The devic was also evaluated wit the HerpeSelectELIA IGa cleared predicate device which is not required for regulatory clearance for typing assay.

# HSV-1 Sensitivity and Specificity

The Focus HerpeSelect 1 Immunoblot IgG was: HSV-1 positive for 170 samples, HSV-1 negative with 128 samples, and HSV Common Antigen band positive for two samples.

The Plexus HerpeSelect 1 agreed with:   
$9 6 . 5 \%$ (164/170) of Immunoblot positives, and   
$9 2 . 2 \%$ (118/128) of Immunoblot negatives.   
The two Immunoblot HSV Common Antigen band positives were both negative in the Plexus.

# HSV-2 Sensitivity and Specificity

The Focus HerpeSelect 2 Immunoblot IgG was: HSV-2 positive for 122 samples, HSV-2 negative with 176 samples, and HSV Common Antigen band positive for two samples.

The Plexus HerpeSelect 2 agreed with:   
$9 4 . 3 \%$ (115/122) of Immunoblot positives, and   
$9 5 . 5 \%$ (168/176) of Immunoblot negatives.   
The two Immunoblot HSV Common Antigen band positives were both negative in the Plexus.

Plexus HerpeSelect 1 IgG Reactivity with Expectant Mothers $\mathbf { \left( n = 3 0 0 \right) }$ EPY   

<table><tr><td rowspan=2 colspan=1>Lab</td><td rowspan=2 colspan=1>Herpe-SelectImmunoblot</td><td rowspan=1 colspan=5>Plexus HerpeSelect-1</td><td rowspan=1 colspan=5>HerpeSelect-1 ELISA</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Sensitivity andSpecificity</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Focus andSite I</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>170</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>96.5% (164/170)95%CI 92.5-98.7%</td><td rowspan=1 colspan=1>170</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>96.5% (164/170)95%CI 92.5-98.7%</td></tr><tr><td rowspan=1 colspan=1>Focus andSite 1</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>92.2% (118/128)95%CI 86.1-96.2%</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>92.2% (118/128)95%CI 86.1-96.2%</td></tr><tr><td rowspan=1 colspan=1>Focus andSite 1</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Na</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Na</td></tr></table>

Plexus HerpeSelect 2 IgG Reactivity with Expectant Mothers $( \mathbf { n } = 3 0 0 )$   

<table><tr><td rowspan=2 colspan=1>Lab</td><td rowspan=2 colspan=1>Herpe-SeelectImmunoblot</td><td rowspan=1 colspan=5>Plexus HerpeSelect-2</td><td rowspan=1 colspan=5>HerpeSelect-2 ELISA</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Ney</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Sensitivity andSpecificity</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Focus andSite 1</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>94.3% (115/122)95%CI 88.5-97.7%</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>97.5%(119/122)95%C1 93.0.99.5%</td></tr><tr><td rowspan=1 colspan=1>Focus andSite 1</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>176</td><td rowspan=1 colspan=1>168</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>95.5% (168/176)95%CI 91.2-98.0%</td><td rowspan=1 colspan=1>176</td><td rowspan=1 colspan=1>166</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>94.3% (166/176)95%CI 89.8-97.2%</td></tr><tr><td rowspan=1 colspan=1>Focus andSite 1</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Na</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Na</td></tr></table>

# Reactivity with Sexually Active Adults $( \mathbf { n } = 3 0 0 )$

Focus $\tan = 1 5 0 ^ { \circ } ,$ and an external investigator $( \mathfrak { n } = \mathrm { { l } } 5 0 )$ assessed the device's reactivity with sera from sexually active Te qly  h b asTextalnva cl bay caSuh Cal nd he  we colecNor States. The gold-standard reference method was the Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG for calculation of sensitivity and specificity. The device was also evaluated with the HerpeSelect2 ELISA $\mathrm { I g G }$ a cleared predicate device which is not required for regulatory clearance for typing assay.

# HSV-1 Sensitivity and Specificity

The Focus HerpeSelect 1 Immunoblot IgG was: HSV-1 positive for 157 samples, HSV-1 negative with 142 samples, and HSV Common Antigen band positive for one sample.

The Plexus HerpeSelect 1 agreed with:   
$9 1 . 0 \%$ (142/156) of Immunoblot positives (one sample was not run on the Plexus device), and $9 6 . 5 \%$ (137/142) of Immunoblot negatives.

# HSV-2 Sensitivity and Specificity

The Focus HerpeSelect 2 Immunoblot IgG was: HSV-2 positive for 109 samples, HSV-2 negative with 190 samples, and HSV Common Antigen band positive for one sample.

The Plexus HerpeSelect 2 agreed with:   
$9 6 . 3 \%$ (105/109) of Immunoblot positives, and   
$9 7 . 4 \%$ (184/189) of Immunoblot negatives (one sample was not run on the Plexus device).

Plexus HerpeSelect 1 IgG Reactivity with Sexually Active Adults $\mathbf { \left( n = 3 0 0 \right) }$   

<table><tr><td rowspan=2 colspan=1>Lab</td><td rowspan=2 colspan=1>Herpe-SelectImmunoblot</td><td rowspan=1 colspan=5>Plexus HerpeSelect-1</td><td rowspan=1 colspan=5>HerpeSelect-1 ELISA</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Sensitivity andSpecificity</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Focus andSite 2</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>91.0% (142/156)95%CI 85.4-95.0%</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>93.6% (147/157)95%C1 88.6-96.9%</td></tr><tr><td rowspan=1 colspan=1>Focus andSite 2</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>96.5% (137/142)95%CI 92.0-98.9%</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>96.5% (137/142)95%CI 92.0-98.9%</td></tr><tr><td rowspan=1 colspan=1>Focus andSite 2</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>na</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>na</td></tr></table>

Plexus HerpeSelect 2 IgG Reactivity with Sexually Active Adults $\mathbf { \left( n = 3 0 0 \right) }$ EPY   

<table><tr><td rowspan=2 colspan=1>Lab</td><td rowspan=2 colspan=1>Herpe-SelectImmunoblot</td><td rowspan=1 colspan=5>Plexus HerpeSelect-2</td><td rowspan=1 colspan=5>HerpeSelect-2 ELISA</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Focus andSite 2</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>96.3% (105/109)95%C1 90.9-99.0%</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>98.2% (107/109)95%CI 93.5-99.8%</td></tr><tr><td rowspan=1 colspan=1>Focus andSite 2</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>189</td><td rowspan=1 colspan=1>184</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>97.4% (184/189)95%CI 93.9-99.1%</td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>186</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>97.9% (186/190)95%C1 94.7-99.4%</td></tr><tr><td rowspan=1 colspan=1>Focus andSite 2</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>na</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>na</td></tr></table>

# Agreement with CDC Panel $( \mathbf { n } = 1 0 0 )$

The following information is from a serum panel obtained from the CDC and tested by Focus Diagnostics. The results are presented as a mens to convey furthr formation on the performance o this assay wi amask, characterized serum panel. This does not imply an endorsement of the assay by the CDC.

The et panelconsists  00 sples.Thi panelcotais duplicate amples f 0 test r The uplicatev to test or reproducibility. There are 16 HSV-1 positive, 7 HSV-2 positive, 11 double-positive and 16 dublenegative sera resulting in 54 HSV-1 positive and 36 HSV-2 positive specimens.

# Determination of positive and negative samples

Of the 54 HSV-1 positive samples, the HerpeSelect® Plexus IgG correctly identified $100 \%$ (54/54).   
Of the 36 HSV-2 positive samples, the HerpeSelect® Plexus IgG correctly identified $100 \%$ (36/36).   
Of the 22 double positive samples, the HerpeSelect® Plexus IgG correctly identified $100 \%$ (22/22).   
Of the 32 double negative samples, the HerpeSelect® Plexus IgG correctly identified $100 \%$ (32/32).

Agreement with CDC Panel $\mathbf { \left( n = 1 0 0 \right) }$   

<table><tr><td rowspan=2 colspan=1>SampleType</td><td rowspan=1 colspan=2>CDC Result</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=4>HerpeSelect-1 Plexus Results</td><td rowspan=1 colspan=4>HerpeSelect-2 Plexus Results</td></tr><tr><td rowspan=1 colspan=1>HSV1</td><td rowspan=1 colspan=1>HSV2</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>HSV-1Positive</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>100% (32/32)95%CI 89.1-100%</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100% (32/32)95%C1 89.1-100%</td></tr><tr><td rowspan=1 colspan=1>HSV-2Positive</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100% (14/14)95%CI 76.8-100%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>100% (14/14)95%CI 76.8-100%</td></tr><tr><td rowspan=1 colspan=1>DualPositive</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>100% (22/22)95%CI 84.6-100%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>100% (22/22)95%C1 84.6-100%</td></tr><tr><td rowspan=1 colspan=1>DualNegative</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100% (32/32)95%C1 89.1-100%</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100% (32/32)95%CI 89.1-100%</td></tr></table>

# CDC Panel Reproducibility

Al paire sea wee correcty entiieThe Focus Diagostics HerpeSelctand Plexus IGidentiied u of 16 paired HSV-1 positive and HSV-2 negative $( 1 0 0 \% )$ , 7 out of 7 paired HSV-2 positive and HSV-1 negative $100 \% )$ , 11 out of 1 1 paired double-positive $( 1 0 0 \% )$ and 16 out of 16 paired double-negative $( \mathrm { l } 0 0 \% )$ samples.

# Specificity with a Low Prevalence Population $( \mathbf { n } = 7 7 )$

Focus $( \mathsf { n } = 7 7 )$ assessed the device's reactivity with sera from a low prevalence population. Focus selected sera from pa 8 nd  yrs ndha bee cl  Se Cl having a history of low sexually transmitted disease prevalence. Focus excluded sera that were submitd for seliieherpei s ndtndhe pat ay oi The s were sequentially selecte, archived andmasked The HerpeSelct Plexus results were compared to theFous HerpeSelect 1 and 2 Immunoblot IgG.

# HSV-1 Reactivity

The Focus HerpeSelect 1 Immunoblot IgG was: HSV-1 positive for 28 samples, HSV-1 negative with 47 samples, and HSV Common Antigen band positive for two samples.

The Plexus HerpeSelect 1 agreed with: $9 6 . 4 \%$ (27/28) of Immunoblot positives (one HSV-1 Immunoblot positive was equivocal in the Plexus device), and $9 7 . 9 \%$ (46/47) of Immunoblot negatives (one HSV-1 Immunoblot negative was positive in the Plexus device).

One Immunoblot HSV Common Antigen band positive was equivocal in the Plexus, and the other sample was Plexus negative.

# HSV-2 Reactivity

The Focus HerpeSelect 2 Immunoblot IgG was: HSV-2 positive or four samples, HSV-2 negative with 71 samples, and HSV Common Antigen band positive for two samples.

The Plexus HerpeSelect 2 agreed with: $7 5 . 0 \%$ (3/4) of Immunoblot positives (one HSV-1 Immunoblot positive was equivocal in the Plexus device), and $100 \%$ (71/71) of Immunoblot negatives (one HSV-1 Immunoblot negative was posiivein the Plexus evice. oth Immoblot H Common Antien band positives were negative in the exus

Specificity with Low Prevalence Population $\left( \mathbf { n } = 7 7 \right)$   

<table><tr><td rowspan=2 colspan=1>HerpeSelectImmunoblot</td><td rowspan=1 colspan=5>Plexus HerpeSelect-1</td><td rowspan=1 colspan=5>Plexus HerpeSelect-2</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Sensitivity andSpecificity</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Sensitivity andSpecificity</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>96.4% (27/28)95%CI 81.6-99.9%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>75.0% (3/4)95%C1 19.4-99.4%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>97.9% (46/47)95%CI 88.7-99.9%</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100% (71/71)95%CI 94.9-100%</td></tr><tr><td rowspan=1 colspan=1>Common</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr></table>

# Cross-reactivity $\bf ( n = 5 1 )$

Focus assessed cross-reactivity with two groups of samples: a "HSV ELISA dual negative" group $\left( \mathsf { n } \mathrm { = } 3 7 \right)$ , and a "HSV ELISA mixed sero-reactivity" group $\scriptstyle ( \ n = 1 4 )$ .

The HSV ELISA dual negative group $\mathrm { ( n { = } } 3 7$ included samples that were sero-negative with both the HerpeSelect- I ELISA IgG and HerpeSelect 2 ELISA IgG, and were sero-positive by at least one of   
a FDA cleared CMV ELISA IgG ( ${ \mathrm { ~  ~ \omega ~ } } _ { \nparallel } = 1 8$ ,   
a home brerw VZV ACIF $\scriptstyle ( \ n = 3 2 )$ +   
a FDA cleared EBV VCA IgG $\scriptstyle ( \mathtt { n } = 3 1 )$   
The HerpeSelect 1 and 2 Plexus IgG was HSV-1 negative with ll but one of the HSV ELISA dual negatives, and equivocal with one sample (the one sample was $\mathrm { C M V + V Z V + }$ and $\mathrm { E B V + }$ ).   
The HerpeSelect 1 and 2 Plexus $\mathrm { I g G }$ was HSV-2 negative with all but one of the HSV ELISA dual negatives, and equivocal with one sample (the one sample was CMV- ${ \mathrm { V Z V } } +$ and $\mathrm { E B V + }$ .   
The HSV ELISA mixed reactivity group $( \mathsf { n } { = } 1 4 )$ included samples that were sero-positive with either the   
HerpeSelect-1 ELISA IgG or HerpeSelect 2 ELISA $\mathrm { I g G }$ , and were sero-positive by at least one of   
a FDA cleared CMV ELISA IgG (HSV-1 neg $\mathfrak { n } = 2$ , HSV-2 neg $\boldsymbol { \mathrm { n } } = \boldsymbol { \mathrm { 9 } }$ ),   
a home brew VZV ACIF (HSV-1 neg $\boldsymbol { \mathsf { n } } = \boldsymbol { \mathsf { I } }$ , HSV-2 neg $\bar { \mathfrak { n } } = 2$ ),   
a FDA cleared EBV VCA IgG (HSV-1 neg $\mathsf n = \mathsf { I }$ , HSV-2 neg $\mathfrak { n } = 0$

The HerpeSelect 1 and 2 Plexus IgG was HSV-1 negative with all of the HSV-1 ELISA negatives in the mixed eactivity group.

The HerpeSelect 1 and 2 Plexus IgG was HSV-2 negative with all of the HSV-2 ELISA negatives in the mixed reactivity group.

Cross-reactivity $\mathbf { ( n = 5 1 ) }$   

<table><tr><td rowspan=2 colspan=1>Cross-reactant</td><td rowspan=2 colspan=1>HSVELISAs</td><td rowspan=1 colspan=4>HerpeSelect-1 Plexus</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>HerpeSelect-2 Plexus</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv*</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>%Pos</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqvt</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>%Pos</td></tr><tr><td rowspan=3 colspan=1>CMV IgG +</td><td rowspan=1 colspan=1>Dual Neg</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5.6% (1/18)95%CI 0.1-27.3%</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/18)95%CI0.0-18.5%</td></tr><tr><td rowspan=1 colspan=1>+/-or-1+</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/2)95%C1 0.0-84.2%</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/9)95%CI 0.0-33.6%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5.0% (1/20)95%CI 0.1-24.9%</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/27)95%C1 0.0-12.8%</td></tr><tr><td rowspan=3 colspan=1>VZV IgG +</td><td rowspan=1 colspan=1>Dual Neg</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.1% (1/32)95%C10.1-16.2%</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.1% (1/32)95%CI0.1-16.2%</td></tr><tr><td rowspan=1 colspan=1>+1-or-1+</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/1)NA</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/2)95%C10.0-84.2%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.0% (1/33)95%C10.1-15.8%</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2.9% (1/34)95%C10.1-15.3%</td></tr><tr><td rowspan=3 colspan=1>EBV IgG +</td><td rowspan=1 colspan=1>Dual Neg</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.2% (1/31)95%CI 0.1-16.7%</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.2% (1/31)95%C1 0.1-16.7%</td></tr><tr><td rowspan=1 colspan=1>+/-or -1+</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/1)NA</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.1% (1/32)95%C1 0.1-16.2%</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.2% (1/31)95%C10.1-16.7%</td></tr></table>

\* The HerpeSelect-1 Plexus was equivocal with one sample, and the sample was $\mathbf { I g } \mathbf { G }$ positive for CMV, VZV and EBV. † The HerpeSelect -2 Plexus was equivocal with one sample, and the sample was $\mathrm { I g G }$ positive for VZV and EBV

# Inter-laboratory Reproducibility and Inter/Intra-assay Reproducibility

F lorC asseed thedevice's nte-laboratory reproduciblity an inter/intra-assayreproducibilityEach of there laboratories tested eleven samples in triplicate on five different days.

Inter-laboratory Reproducibility and Inter/Intra-assay Reproducibilitya   

<table><tr><td rowspan=3 colspan=1>Sample</td><td rowspan=1 colspan=5>HerpeSelect 1 Plexus IgG Results</td><td rowspan=1 colspan=5>HerpeSelect 2 Plexus IgG ResuIts</td></tr><tr><td rowspan=1 colspan=3>Intra- and Inter-assay</td><td rowspan=1 colspan=2>Inter-Lab</td><td rowspan=1 colspan=3>Intra- and Inter-assay</td><td rowspan=1 colspan=2>Inter-Lab</td></tr><tr><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>Intra-assay% CV</td><td rowspan=1 colspan=1>Inter-assay% CV</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>Intra-assay% CV</td><td rowspan=1 colspan=1>Inter-assay% CV</td><td rowspan=1 colspan=1>McanIndex</td><td rowspan=1 colspan=1>% CV</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>4.93</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>4.94</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>3.88</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>3.87</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>4.24</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>4.22</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>4.90</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>4.89</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3.87</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>3.86</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>3.36</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>3.35</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>3.27</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>3.25</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>4.56</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>4.55</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3.24</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>3.22</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.55</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>2.54</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3.04</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>3.02</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.71</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>2.70</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>12b</td><td rowspan=1 colspan=1>2.13</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>2.13</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>1.87</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>1.87</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>28.3</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>22.6</td></tr><tr><td rowspan=1 colspan=1>10c</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>9.9</td><td rowspan=1 colspan=1>213.1</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>59.0</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>11.4</td><td rowspan=1 colspan=1>334.2</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>103.8</td></tr><tr><td rowspan=1 colspan=1>10d$</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>15.8</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>11.5</td><td rowspan=1 colspan=1>41.7</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>38.3</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>16.3</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>23.7</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>17.3</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>16.0</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>39.8</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>38.1</td></tr></table>

Positive Control was run in those wells since the indices were about 1.9 for both $\mathbf { g } \mathbf { G } \mathbf { l }$ and $\mathsf { g G 2 }$ 0 Samples 11 did not have sufficient volume to be sent to investigators. indices were about 2.7 for both $\mathrm { \ g G 1 }$ and $\mathbf { g } \mathbf { G } 2$ . indices wcre about 2.7 for both $\mathrm { g G 1 }$ and $\mathbf { g } \mathbf { G } 2$ .

# Inter-Lot Reproducibility

Fv Rytv pi  The were run in triplicate. Each lot had a different set of $\mathrm { g } \mathrm { G } \mathfrak { s l }$ and $\mathbf { g } \mathbf { G } 2$ beads, a different lot of conjugate (made from 2 diffeent stock conjugates), and a different ot f calibrator made from  diffeent cominationso positive and negative sera). The results of the studies are summarized in the tables below:

Inter-lot Reproducibility   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=1 colspan=2>HSV-1</td><td rowspan=1 colspan=2>HSV-2</td></tr><tr><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>Inter-Lot%CV</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>Inter-Lot%CV</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>5.20</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>3.90</td><td rowspan=1 colspan=1>12.8</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>4.36</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>4.76</td><td rowspan=1 colspan=1>9.2</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3.60</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>3.19</td><td rowspan=1 colspan=1>9.3</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3.29</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>2.54</td><td rowspan=1 colspan=1>6.4</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>3.23</td><td rowspan=1 colspan=1>11.3</td><td rowspan=1 colspan=1>4.45</td><td rowspan=1 colspan=1>9.4</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3.14</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>2.73</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>12/14*</td><td rowspan=1 colspan=1>2.22</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>1.86</td><td rowspan=1 colspan=1>7.8</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>17.0</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>50.9</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>31.3</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>21.8</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>45.6</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>24.9</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>50.6</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>26.9</td></tr></table>

Samples 11 and 13 did not have sufficient volume to bc sent to investigators.

Constance Bridges, MBA, RAC, ASQ-CBA Director, Regulatory and Compliance   
Focus Diagnostics, Inc.   
10703 Progress Way   
Cypress, California 90630

OCT 5  2007

Re: k071511 Trade/Device Name: PlexusTM HerpeSelect $^ \mathrm { \textregistered }$ HSV 1 and $2 \mathrm { \ l g } \mathrm { G }$ (with software) Regulation Number: 21CFR 866.3305 Regulation Name: Herpes simplex virus serological reagents Regulatory Class: Class II Product Code: MXJ, MYF Dated: September 5, 2007 Received: September 10, 2007

Dear Ms. Bridges:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276- 0100.Als0, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jay a

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# 510(k) Number (if known): K071511

Device Name:

PlexusTM HerpeSelect $\textsuperscript { \textregistered }$ HSV 1 and $2 \mathrm { I g } \mathrm { G }$ (with software)

Indications for Use:

The Focus Diagnostics PlexusTM HerpeSelect $^ \mathrm { \textregistered }$ HSV 1 and 2 IgG (with software) is intended for qualitatively detecting the presence or absence of human IgG antibodies to HSV-1 and HSV-2 in human sera. The test is indicated for pregnant women and sexually active adults, as an aid for presumptively diagnosing HSV-1 and HSV-2 infection. The predictive value of a positive or negative result depends on the population's prevalence and the pretest likelihood of HSV-1 and HSV-2 infection. The test is not intended for donor screening or for self-testing. The performance of this assay has not been established for use in a pediatric population, for neonatal screening, for testing of immunocompromised patients, for use by a point of care facility or for use with automated equipment.